Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

Tracy A. McGowan; Yanqing Zhu; Kumar Sharma

doi:10.1007/s11892-004-0055-z

Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

Tracy A. McGowan
, Yanqing Zhu
, Kumar Sharma

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

Original language	English (US)
Pages (from-to)	447-454
Number of pages	8
Journal	Current Diabetes Reports
Volume	4
Issue number	6
DOIs	https://doi.org/10.1007/s11892-004-0055-z
State	Published - Dec 2004
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s11892-004-0055-z

Cite this

@article{819d65b6948942b2b4355928ac7bebba,

title = "Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy",

abstract = "Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.",

author = "McGowan, \{Tracy A.\} and Yanqing Zhu and Kumar Sharma",

note = "Funding Information: This review was supported in part with funding from National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK63017) to KS and TAM.",

year = "2004",

month = dec,

doi = "10.1007/s11892-004-0055-z",

language = "English (US)",

volume = "4",

pages = "447--454",

journal = "Current Diabetes Reports",

issn = "1534-4827",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Transforming growth factor-beta

T2 - A clinical target for the treatment of diabetic nephropathy

AU - McGowan, Tracy A.

AU - Zhu, Yanqing

AU - Sharma, Kumar

N1 - Funding Information: This review was supported in part with funding from National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK63017) to KS and TAM.

PY - 2004/12

Y1 - 2004/12

N2 - Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

AB - Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming grcmdh factor-β (TGF-β) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-β on matrix accumulation but have also found that blocking TGF-β may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-β in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

UR - https://www.scopus.com/pages/publications/12144264716

UR - https://www.scopus.com/pages/publications/12144264716#tab=citedBy

U2 - 10.1007/s11892-004-0055-z

DO - 10.1007/s11892-004-0055-z

M3 - Review article

C2 - 15539010

AN - SCOPUS:12144264716

SN - 1534-4827

VL - 4

SP - 447

EP - 454

JO - Current Diabetes Reports

JF - Current Diabetes Reports

IS - 6

ER -

Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this